Omalizumab-Induced Remission and Steroid Withdrawal in Refractory Eosinophilic Gastroenteritis with Severe Hypereosinophilia: A Case Report

Zhirong Du,1 Weixun Zhou,2 Ji Li,3 Li Ma,4 Qingli Zhu,4 Yuxiang Zhi1 1Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People’s Republic of China; 2Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, People’s Republic of China; 3Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, People’s Republic of China; 4Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, People’s Republic of ChinaCorrespondence: Yuxiang Zhi, Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People’s Republic of China, Email yuxiang_zhi@126.comAbstract: Eosinophilic gastroenteritis (EGE) is a rare, immune-mediated disorder characterized by pathological eosinophilic infiltration of the gastrointestinal tract. Corticosteroids are the primary treatment for EGE, but managing patients who are corticosteroid-dependent can be challenging. This report describes a 33-year-old female patient with EGE and severe hypereosinophilia, who was corticosteroid-dependent and had been on long-term oral corticosteroids for 5 years with an increasing maintenance dose. The patient achieved effective treatment with omalizumab without adverse reactions. This case provides evidence for the efficacy and safety of omalizumab in patients with corticosteroid-dependent eosinophilic gastroenteritis and severe hypereosinophilia.Keywords: eosinophilic gastroenteritis, hypereosinophilia, omalizumab